SEC Filing Summary: Obalon Therapeutics, Inc. (OBLN)
Business Context and Reporting Period
This Form 8-K was filed on November 6, 2020, by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc., as noted in the metadata request). The filing reports financial results for the three and nine months ended September 30, 2020. The company is an emerging growth company incorporated in Delaware with principal executive offices in Carlsbad, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It serves as a notification that results for the three and nine months ended September 30, 2020, have been reported.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information furnished, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the three and nine months ended September 30, 2020, by reviewing Exhibit 99.1 (Press Release).
- Confirm the company's cash position and burn rate as detailed in the full financial statements referenced in the press release.
- Review the full press release for any updates on clinical trial progress or regulatory milestones not summarized in this 8-K.
- Note that the registrant name in the filing is Obalon Therapeutics, Inc., distinct from the metadata field "Vyome Holdings, Inc."